Gene Therapy Market Comprehensive Study 2018: Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, and NewLink Genetics Corp

Global Gene Therapy Market is expected to reach USD 3928.86 Million by 2025, from USD 855 Million in 2017 growing at a CAGR of 21.5% during the forecast period of 2018 to 2025.

Global Gene Therapy Market, By Vector Type (Viral Vector, Non-Viral Vector), Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, Other Diseases), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, Others), End Users (Pharmaceutical Companies, Research Institutions, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East And Africa)- Industry Trends and Forecast to 2025

Get Sample PDF Report at https://databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-therapy-market

Market Drivers:

• Increase in population.
• Because of the investment towards the research and developments sectors.
• Enhancement of the rare diseases
• Awareness towards the rare diseases
• Because of high initiatives and governments funding for gene therapy development.

Gene therapy progress aims to cure rare diseases and some hereditary diseases caused by a mutated or faulty gene. Moreover, ever-increasing need for new cures for orphan diseases and rising incidence of cancer caused due to mutations in genes are likely to stir up the demand for gene therapy. Gene therapy works by repairing, repressing or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function.
For instance, according to World Health Organization (WHO), in 2015, around 8.8 million deaths were because of cancer and globally, approximately 1 in 6 deaths were because of cancer. It was also reported that low income countries have only 26% of pathology facilities for public in 2017. Whereas, 90% of high-income countries stated that treatment facilities were available compared to less than 30% of low-income countries. The total annual economic cost of cancer in 2010 was estimated at approximately US$ 1.16 trillion.
According to the Food and Drug Administration (FDA), in November 2017, indicated that gene therapies would qualify for a fast approval process, which would bring more therapies to market faster. According to the US gene therapy, space has expanded significantly, underlined by the fact that over 55% of completed and ongoing trials are located in this geographic in 2017. According to The National Institutes of Health nearly 7,000 rare diseases affect more than 25 million Americans. About 80 percent of rare diseases are caused by a single-gene defect and about half of all rare diseases affect children. Since most rare diseases have no approved therapies, there is a significant unmet need. Hence due to increase in the death rates and growing awareness for the development and rare diseases will lead the growth of market for gene therapy.

Contact us For More Inquiry here at https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-gene-therapy-market

Global Gene Therapy Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of absorbable and non-absorbable sutures market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors

• Novartis,
• Kite Pharma Inc.,
• GlaxoSmithKline PLC,
• Spark Therapeutics Inc.,
• Bluebird bio Inc.,
• Genethon,
• Transgene SA,
• Applied Genetic Technologies Corporation,
• Oxford BioMedica, and
• NewLink Genetics Corp,
• UniQure N.V,
• Juno Therapeutics,
• Celgene Corporation,
• Shire Plc,
• Sangamo Biosciences,
• Dimension Therapeutics,
• Voyager Therapeutics,
• Human Stem Cell Institute,
• Bristol Myer’s Squibb,
• Chiesi Farmaceutici S.p.A.,
• Adaptimmune Therapeutics plc,
• Advantagene,
• Epeius Biotechnologies,
• Abeona Therapeutics,
• Merck KGaA among others.

Request for Detailed TOC at https://databridgemarketresearch.com/toc/?dbmr=global-gene-therapy-market

If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.